Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06573411
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-24
Brief Title:
Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy A Multicenter Randomized Double-Blind Placebo-Controlled Clinical Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a prospective randomized multicenter double-blinded placebo-controlled trial Eighty-eight patients with primary membranous nephropathy PMN will be randomly divided into the intervention and control groups The intervention group will be administered maximum tolerable dose of ACEIARB and finerenone 20 mg QD Control patients will be administered maximum tolerable dose of ACEIARB and a placebo The primary endpoint is the relative change in urinary protein content from baseline to 6 months
Detailed Description:
After more than 4 weeks of maximum tolerated dose of ACEIARB the patients will be randomly divided into the control and intervention groups in a 11 ratio in a double-blinded manner The intervention group will then be administered finerenone 20 mg QD while control cases will receive a placebo
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None